Updates in Head and Neck Cancer Treatment: Integrating Checkpoint Inhibitor Therapy to Improve Outcomes - a podcast by ReachMD

CME credits: 0.25

Valid until: 30-07-2022

Claim your CME credit at https://reachmd.com/programs/cme/updates-head-and-neck-cancer-treatment-integrating-checkpoint-inhibitor-therapy-improve-outcomes/12701/

Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD